ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,043,343 | +2040.0% | 38,443 | +2323.9% | 0.03% | +1550.0% |
| Q2 2023 | $48,754 | +68567.6% | 1,586 | -19.6% | 0.00% | 0.0% |
| Q1 2023 | $71 | -87.0% | 1,973 | -85.7% | 0.00% | -91.3% |
| Q4 2022 | $546 | -99.5% | 13,815 | +396.9% | 0.02% | +1050.0% |
| Q3 2022 | $112,000 | -57.4% | 2,780 | -55.5% | 0.00% | -66.7% |
| Q2 2022 | $263,000 | +14.8% | 6,245 | +6.0% | 0.01% | +200.0% |
| Q1 2022 | $229,000 | -64.1% | 5,889 | -63.2% | 0.00% | -81.8% |
| Q4 2021 | $638,000 | +1019.3% | 15,998 | +925.5% | 0.01% | +1000.0% |
| Q3 2021 | $57,000 | -95.1% | 1,560 | -94.5% | 0.00% | -96.7% |
| Q2 2021 | $1,172,000 | +501.0% | 28,607 | +539.8% | 0.03% | +900.0% |
| Q1 2021 | $195,000 | +89.3% | 4,471 | +117.4% | 0.00% | 0.0% |
| Q4 2020 | $103,000 | +390.5% | 2,057 | +312.2% | 0.00% | – |
| Q3 2020 | $21,000 | – | 499 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |